Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Nektar Therapeutics (NKTR) Announces Initiation of a Phase 1b Clinical Study of NKTR-358
May 8, 2018 8:36 AM EDTNektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class regulatory T cell stimulator. NKTR-358 selectively stimulates the proliferation and activation of regulatory T cells (Tregs) in the body in order to restore the body's self-tolerance mechanisms. Unlike immunosuppressant medicines that treat the symptoms of autoimmune disease by inhibiting the entire immune system which can cause unwanted side effects, NKTR-358 is designed to correct the underlying... More



